End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 EUR | 0.00% | +0.34% | -35.87% |
Sales 2024 * | 1.05M 1.12M | Sales 2025 * | 1.6M 1.71M | Capitalization | 17.95M 19.23M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | 1M 1.07M | EV / Sales 2024 * | 17.5 x |
Net Debt 2024 * | 450K 482K | Net Debt 2025 * | 10.55M 11.3M | EV / Sales 2025 * | 17.8 x |
P/E ratio 2024 * |
-2.1
x | P/E ratio 2025 * |
-3.11
x | Employees | 68 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
Latest transcript on PHAXIAM Therapeutics S.A.
1 week | +0.34% | ||
Current month | -1.01% | ||
1 month | -1.01% | ||
3 months | -24.74% | ||
6 months | -34.52% | ||
Current year | -35.87% |
Managers | Title | Age | Since |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 2.955 | +0.17% | 1,446 |
24-04-26 | 2.95 | 0.00% | 16,261 |
24-04-25 | 2.95 | +1.20% | 941 |
24-04-24 | 2.915 | -0.17% | 1,540 |
24-04-23 | 2.92 | -0.68% | 1,047 |
End-of-day quote Euronext Paris, April 25, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.87% | 19.13M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- PHXM Stock